1. |
Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferonalpha- based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int, 2009, 22(5): 562-567.
|
2. |
Nanmoku K, Imaizumi R, Toj imbara T, e t al . Ef fect s of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. Transplant Proc, 2008, 40(7): 2382-2385.
|
3. |
Rashid A, Abboud O, Al-Kaabi S, et al. The Impact of Hepatitis C Infection and Antiviral Therapy on clinical Outcome in Renal Transplantation Recipients. Saudi J Kidney Dis Transpl, 1999, 10(1): 31-35.
|
4. |
Montalbano M, Pasulo L, Sonzogni A, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol, 2007, 41(2): 216-220.
|
5. |
Sharma RK, Bansal SB, Gupta A, et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant, 2006, 20(6): 677-683.
|
6. |
Carbognin SJ, Solomon NM, Yeo FE, et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant, 2006, 6(7): 1746-1751.
|
7. |
Zeman M, Campbel l P, Bain VG. Hepat i t is C eradicat ion and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol, 2006, 20(6): 427-431.
|
8. |
Konishi I, Horiike N, Michitaka K, et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy. Intern Med, 2004, 43(10): 931-934.
|
9. |
Shu KH, Lan JL, Wu MJ, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation, 2004, 77(12): 1894-1896.
|
10. |
Tang S, Cheng IK, Leung VK, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol, 2003, 39(5): 875-878.
|
11. |
Luciani G, Bossola M, Muscaritoli M, et al. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol, 2003, 16(3): 417-420.
|
12. |
Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant, 2003, 3(1): 74-78.
|
13. |
Schmitz V, Kiessling A, Bahra M, et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant, 2007, 12(3): 22-27.
|
14. |
Kamar N, Boulestin A, Selves J, et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol, 2005, 76(1): 61-68.
|
15. |
Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation, 2004, 78(6): 853-857.
|
16. |
Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis, 2003, 42(1): 184-192.
|
17. |
Fabrizi F, Lunghi G, Dixit V, et al. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Alimentary Pharmacology and Therapeutics, 2006, 24(10): 1413-1422.
|
18. |
唐晓鹏, 赵洪雯, 余荣杰, 等. 小剂量干扰素α联合利巴韦林治疗肾移植术后继发丙型病毒性肝炎患者的疗效观察. 第三军医大学学报, 2008, 30(2): 117-119.
|
19. |
Pereira BJG, Natov SN, Bouthot BA, et al. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int, 1998, 53: 1374-1381.
|
20. |
Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology, 1999, 29: 257-263.
|